Phase 2 Study of Ivonescimab with Chemotherapy and Investigational Drugs as First Treatment for Extensive-Stage Small Cell Lung Cancer in Adults

What this Trial Is About

Researchers are evaluating different combinations of the drug Ivonescimab with chemotherapy and other investigational drugs for the initial treatment of adults with extensive-stage small cell lung cancer ES-SCLC. The study aims to learn about the side effects participants experience and how well these treatments work to shrink tumors. This Phase II trial compares three groups to find out which combination is most effective and safe. Participants will be randomly assigned to one of three groups. All groups receive Ivonescimab and chemotherapy with etoposide and carboplatin during an initial treatment phase lasting about 3 months. Group 1 also receives AK117, Group 2 receives Cadonilimab, and Group 3 receives Ivonescimab with chemotherapy only. If the treatment is effective and side effects are manageable, participants continue with a maintenance phase using only the study drugs without chemotherapy for up to 2 years. During the study, participants will attend regular clinic visits for check-ups, blood tests, and imaging scans like CT scans to monitor their response to treatment. Researchers will measure how well the tumors respond, the duration and time to response, progression-free survival, overall survival, and the incidence of side effects. Monitoring also includes checking drug concentrations and antibodies. The study participation can last up to 5 years for survival follow-up.

A Study of Ivonescimab in First-Line ES-SCLC